Evidence check: CYP1A2 in the context of menopause

The provided context documents do not contain specific information on CYP1A2 in relation to menopause. CYP1A2 is a well-studied gene involved in drug and caffeine metabolism, and it also plays a role in estrogen metabolism. During menopause, declining estrogen levels may reduce CYP1A2 activity, potentially increasing caffeine sensitivity. However, the evidence for direct clinical recommendations (e.g., adjusting caffeine intake based on genotype) is moderate, based mainly on pharmacokinetic and observational studies rather than robust RCTs. A consumer DNA test for CYP1A2 variants (e.g., rs762551) can indicate metabolic tendencies, but enzyme activity is also influenced by hormones, medications, and lifestyle. Without validated reference ranges for menopausal women, interpretation remains speculative. Consumers should approach such tests with caution and discuss results with a healthcare provider.